Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 12, 2024

BUY
$8.84 - $18.7 $89,929 - $190,235
10,173 New
10,173 $141,000
Q2 2021

Aug 16, 2021

BUY
$31.92 - $60.25 $159,600 - $301,250
5,000 New
5,000 $301,000

Others Institutions Holding VERV

About Verve Therapeutics, Inc.


  • Ticker VERV
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,942,300
  • Market Cap $489M
  • Description
  • Verve Therapeutics, Inc., a genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases. Its lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver. The company also engages in the development of ANGPTL3 program t...
More about VERV
Track This Portfolio

Track Capstone Investment Advisors, LLC Portfolio

Follow Capstone Investment Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Capstone Investment Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Capstone Investment Advisors, LLC with notifications on news.